Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC) has entered a deal with an unnamed distributor from the Alpine Republic of Switzerland to start selling its medical cannabis cultivars in the country.
On Wednesday, the company announced it will start selling its medical cannabis cultivars Khiron Gelato 19/1 and Khiron Caramel 5/7 in the mountainous region.
Last August, the company announced the acquisition of a German EU GMP-certified manufacturer and wholesaler Pharmadrug GmbH which has helped the company in obtaining import and export permits across Germany and the United Kingdom. The acquisition helped the company to pave the way into Switzerland and build a reputation in the European market.
The company will start selling seven medical cannabis SKUs over the next weeks and celebrated its first-year anniversary of entering the U.K. with an expanded portfolio adding three exclusive products.
Khiron’s stock stayed flat on Wednesday at $0.085 on the Canadian Ventures Exchange.
Read more: Khiron launches new pot products in Europe
Read more: Khiron drops revenue by 4% to $4.5M in Q2
“Khiron continues its tradition of entering new markets early and furthering our goal of improving the lives of our patients in all our target markets. We are very excited to improve lives of patients in Switzerland now,” Khiron Europe president Franziska Katterbach said.
“I am equally pleased that our one-year anniversary of Zerenia Clinics UK is marked by the very good feedback from patients treated in our clinic. This reinforces our patient-first and quality first-approach which we will now bring to Switzerland as well.”
According to a survey by Khiron, all patients at Khiron’s Zerenia clinics in the UK responded that they are 100 per cent satisfied that their quality of life has improved since starting a cannabinoid treatment.